IO-TKI Findings in nccRCC from KEYNOTE-B61

Opinion
Video

Following the 2024 ASCO Annual Meeting, Martin H. Voss, MD, discusses long-term follow-up data from the phase 2 KEYNOTE-B61 trial investigating pembrolizumab plus lenvatinib in the first-line treatment of advanced non–clear cell RCC.

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Mazyar Shadman, MD, MPH, an expert on CLL
Mazyar Shadman, MD, MPH, an expert on CLL
Mazyar Shadman, MD, MPH, an expert on CLL
Related Content